Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Many Physicians Lack Accurate Knowledge about Medicinal Narcotics
September 29, 2008
- Pure Pharma Business Model Approaching the End: Mr K. Masuzoe
September 29, 2008
- Avastin Effective in Patients with or without K-ras Gene Mutation
September 29, 2008
- Quintiles to Provide Lab Data Directly Comparable with Those from Other Countries
September 29, 2008
- Mylan to Increase Number of MRs to 300, Open 4 More Offices
September 29, 2008
- Astellas Ties Up with Maxygen to Develop Drugs for Autoimmune Diseases, Transplant Rejection
September 29, 2008
- More Prescriptions than Expected Prohibit Use of Generics: Mr Urushibata
September 29, 2008
- Erbitux Launched by Merck Serono and Bristol-Myers
September 29, 2008
- Draft Ordinance Published in Preparation for Full Enforcement of Amended PAL
September 29, 2008
- NanoCarrier Ties Up with Taiwan Company for Nanoplatin
September 29, 2008
- Pfizer to Start Clinical Trial for Fibromyalgia
September 29, 2008
- Bristol-Myers Applies for Abatacept
September 29, 2008
- R&D NEWS IN BRIEF
September 29, 2008
- NEW PRODUCTS／Kyowa Medex Launches New Reagent to Determine HDL-C
September 29, 2008
- NEW PRODUCT／Julina Launched as Japan's First Oral Estradiol Product
September 29, 2008
- Will Distribution Practices Be Improved? Part 3
September 29, 2008
- TOPICS／Prof. Yamanaka's iPS Cell Preparation Method Patented in Japan
September 29, 2008
- Drugs Will Continue to Be a Core Business of New Meiji Company
September 29, 2008
- Number of Centenarians Up to 36,276
September 29, 2008
- 75% of People Dissatisfied with Current Social Security System
September 29, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…